EN DE
Watch LEXARIA BIOSCIENCE CORP. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

LEXARIA BIOSCIENCE CORP. (LEXX) fair value: what the stock is really worth

As of Oct 30, 2026: fair value (intrinsic value) of LEXARIA BIOSCIENCE CORP. stock $1.08, price $3.49, upside -69.1%, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US · Based in Canada

LB LEXARIA BIOSCIENCE CORP. logo Thin data Oct 29, 2026

LEXARIA BIOSCIENCE CORP.

LEXX · US
Very expensive, in a downtrend

Our calculation puts a fair price 69% below what the stock costs today.

Quality 50/100
Mixed Growth (revenue 5y +12.9 %/yr in USD)
Revenue last quarter 89% below a year ago.
Fair value $1.08 · Strongly overvalued (−69.1%)
Negative free cash flow
Trails peers (1/6)
Narrow moat 23/100 · thin data
Thin data
Watch LEXARIA BIOSCIENCE CORP. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$105.30 $2.60 Fair Value $1.08 Jul 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year. As of Oct 29, 2026.

How to read this chart

60‑month range $2.60 – $105.30 · fair‑value band $0.7200 – $1.35 · the $3.49 price screens above the $1.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 29, 2026.

Follow LEXARIA BIOSCIENCE in your weekly email

Every Wednesday you see whether LEXARIA BIOSCIENCE is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Lexaria Bioscience Corp. operates as a biotechnology company.

Show moreShow less

The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods.

Its DehydraTECH is used with a range of active molecules, including glucagon-like peptide-1 drugs (GLP-1) and glucose -dependent insulinotropic polypeptide drugs (GIP), vitamins, pain medications, hormones, phosphodiesterase type 5 (PDE5) inhibitors, antivirals, nicotine and its analogs, and cannabinoids.

The company's DehydraTECH technology is applied to various therapeutic indications, such as diabetes, weight loss, hypertension, epilepsy, and heart disease; is implemented in a multitude of ingestible or topically administered product formats comprising oral suspensions, tablets, capsules, foods, beverages, and oral products; and is suitable for a variety of product formats, including pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods.

The company was formerly known as Lexaria Corp. and changed its name to Lexaria Bioscience Corp. in April 2016. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.

Stock analysis

LEXARIA BIOSCIENCE CORP. (LEXX) currently trades at $3.49, while our model-based Fair Value estimate is $1.08, 69.1% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 82/100, which puts the data coverage at low.

Scenario range: $0.7200 (bear) to $1.35 (bull), the price of $3.49 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

LEXARIA BIOSCIENCE CORP. reported revenue of $706K in FY2025 versus $723K in FY2021, a compound −0.6%/yr. Reported net income was −$11.9M in FY2025.

Key figures

Market cap $7.0M Micro · P/S ratio 35.8 · EPS (TTM) $−5.10 · Return on equity −163% · Return on assets (EBIT) −138% · Operating margin −3,863% · Revenue growth (YoY) −88.5% · Free cash flow −$10.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 23 out of 100 (low confidence).

What moves the price

The share trades about 83% below its 52-week high and 34% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −69%, LEXX screens richer than that median.

Fair Value models

Bear $0.7200 Fair Value $1.08 Bull $1.35
Price $3.49 · Upside -69.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
NCAV (Graham) $0.7200 $1.08 $1.35 52
All 1 models by family
Asset-Based
NCAV (Graham) $0.7200 $1.08 $1.35 52

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 7
How much profit the company makes from its sales and capital
Quality Growth 51
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 75
Debt, balance sheet and risk of trouble
Investment 97
Does it invest with discipline instead of growing at any price?
Low Volatility 46
How calm the share price moves, does not count
Price momentum 6
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 3
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+52.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.9%
Start year 2020 (pandemic)
Revenue growth 20 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+19.4%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−1,078.9% (2020) → −1,683.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

LEXX screens overvalued: fair value 69% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Earlier news

News mood ⓘNews mood, the average tone of recent news (45 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation. Positive
Recent news coverage is more positive than average.

Compare LEXARIA BIOSCIENCE CORP. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 589 stocks

Beats the industry median on 1/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 50 · Above median
Fair Value upside −69.1% · Below median
Growth and dividend
Revenue growth (quarter YoY) −88.5% · Bottom 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B 2.33× · Pricier than median
P/S (12 months) 35.83× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $927.89 $1,275 +37% vs LEXX
Vertex Pharmaceuticals Incorporated VRTX $540.00 $594.00 +10% vs LEXX
Samsung Biologics Co 207940 1,487,000 KRW 1,635,700 KRW +10% vs LEXX
Genmab A/S GMAB kr 3,912 kr 4,303 +10% vs LEXX
WuXi Biologics (Cayman) Inc 2269 HK$45.06 HK$49.57 +10% vs LEXX
argenx SE ARGX $882.48 $908.40 +3% vs LEXX
CSL Limited CSL A$200.73 A$178.58 −11% vs LEXX
BeOne Medicines AG ONC $370.33 $254.12 −31% vs LEXX
Celltrion, Inc 068270 189,300 KRW 74,945 KRW −60% vs LEXX
Royalty Pharma plc RPRX $67.18 $19.01 −72% vs LEXX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

LEXARIA BIOSCIENCE CORP. · Fair Value
$1.08 −69%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "LEXARIA BIOSCIENCE CORP. Fair Value". https://www.fairvalue-calculator.com/stock/LEXX

Frequently asked questions

Is LEXARIA BIOSCIENCE CORP. (LEXX) overvalued or undervalued?
As of Oct 29, 2026, our model estimates a fair value of $1.08 versus a price of $3.49, about −69% upside (overvalued).
What is the fair value of LEXX?
Our model-based fair value for LEXARIA BIOSCIENCE CORP. is $1.08 (as of Oct 29, 2026), built from audited fundamentals. The current price: $3.49.
What is the quality score of LEXX?
LEXARIA BIOSCIENCE CORP. has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for LEXARIA BIOSCIENCE CORP. (LEXX)?
Our model-based price target is the fair value of $1.08 (as of Oct 29, 2026) from 1 valuation models. Cautious scenario $0.7200, optimistic scenario $1.35. It is a calculation from audited fundamentals, not an analyst target.
What is the LEXARIA BIOSCIENCE CORP. stock forecast for 2026?
Our models put fair value at $1.08, about −69% upside versus a price of $3.49 (overvalued). Cautious scenario $0.7200, optimistic scenario $1.35. The calculation is refreshed regularly with new filings.
What is the intrinsic value of LEXARIA BIOSCIENCE CORP. (LEXX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For LEXARIA BIOSCIENCE CORP. it is $1.08 per share (as of Oct 29, 2026), against a price of $3.49. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is LEXARIA BIOSCIENCE CORP. stock overvalued or undervalued in 2026?
As of Oct 29, 2026, LEXX trades above its calculated fair value: price $3.49, fair value $1.08, a gap of about −69% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of LEXX?
No. The price is what the market pays today ($3.49); the fair value is what the company's own numbers justify ($1.08). For LEXARIA BIOSCIENCE CORP. the two are $2.41 per share apart. That gap is exactly why we show both numbers side by side.
How much is LEXARIA BIOSCIENCE CORP. worth?
The market values LEXARIA BIOSCIENCE CORP. at about $7.0M (market capitalisation, as of Oct 29, 2026). Per share that is $3.49; our models calculate a fair value of $1.08 per share.
What do the bullish and bearish scenarios say about LEXX?
Our models span a range for LEXARIA BIOSCIENCE CORP.: cautious scenario $0.7200, base $1.08, optimistic $1.35 per share (as of Oct 29, 2026, price $3.49). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of LEXARIA BIOSCIENCE CORP. (LEXX)?
Balance-sheet figures for LEXARIA BIOSCIENCE CORP. (as of Oct 29, 2026): return on equity −162.8%. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is LEXX from its 52-week high?
LEXARIA BIOSCIENCE CORP. trades at $3.49, about 83% below its 52-week high of $20.10 and 34% above the low of $2.60 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $1.08 is for.
Which stocks are comparable to LEXARIA BIOSCIENCE CORP.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is LEXARIA BIOSCIENCE CORP. stock attractive at the current price?
The data as of Oct 29, 2026: price $3.49, calculated fair value $1.08 (−69%), Quality Score 50/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of LEXX calculated?
We run LEXARIA BIOSCIENCE CORP. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1.08, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.5 % above its aggregate fair value. LEXARIA BIOSCIENCE CORP. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of LEXARIA BIOSCIENCE CORP. (LEXX)?
The closing price on Oct 30, 2026 was $3.49. Our model-based fair value is $1.08, about −69% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with LEXARIA BIOSCIENCE CORP. right now?
The price sits above even our optimistic bull case ($1.35). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.7200 to $1.35) leaves room in how you read the outcome.

Key figures of LEXARIA BIOSCIENCE CORP.

How large is the market capitalisation of LEXARIA BIOSCIENCE CORP. (LEXX)?
The market capitalisation of LEXARIA BIOSCIENCE CORP. is $7.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of LEXARIA BIOSCIENCE CORP. (LEXX)?
The price-to-sales ratio of LEXARIA BIOSCIENCE CORP. is 35.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of LEXARIA BIOSCIENCE CORP. (LEXX)?
Earnings per share at LEXARIA BIOSCIENCE CORP. are $−5.10. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of LEXARIA BIOSCIENCE CORP. (LEXX)?
The return on equity (ROE) of LEXARIA BIOSCIENCE CORP. is −163% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of LEXARIA BIOSCIENCE CORP. (LEXX)?
On an EBIT basis the return on assets of LEXARIA BIOSCIENCE CORP. is −138% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of LEXARIA BIOSCIENCE CORP. (LEXX)?
The operating margin of LEXARIA BIOSCIENCE CORP. is −3,863% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at LEXARIA BIOSCIENCE CORP. (LEXX)?
Revenue at LEXARIA BIOSCIENCE CORP. is growing −88.5% versus a year earlier (3y avg +40.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does LEXARIA BIOSCIENCE CORP. (LEXX) generate?
The free cash flow of LEXARIA BIOSCIENCE CORP. is −$10.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does LEXARIA BIOSCIENCE CORP. (LEXX) hold?
LEXARIA BIOSCIENCE CORP. holds more cash than debt, $1.7M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch LEXARIA BIOSCIENCE CORP. in the live analysis

One click puts LEXARIA BIOSCIENCE CORP. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.